This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the obesity and diabetes drugmaker, faces a growing field of challengers chasing a weight loss market that could reach $100 billion in annual sales. Shares rose about 3.6% to $1,192.91 at 10.51am ET Time on Thursday morning, measured against Wednesday's $1,150.99 close. Warning! GuruFocus has detected 3 Warning Sign with AVGO. Is LLY fairly valued? Test your thesis with our free DCF calculator.LLY GF Value chart Lilly has a head start challengers cannot buy overnight. Its second-quarter revenue surged 48% to $23 billion, powered chiefly by demand for Mounjaro and Zepbound. The company also has the approved Foundayo pill and retatrutide in late-stage development.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.